FIGURE 4.

Care pathways and predictors of response for biologics in asthma. CRSwNP: chronic rhinosinusitis with nasal polyposis; CSU: chronic spontaneous urticaria; F_ENO: fractional exhaled nitric oxide; IgE: immunoglobulin E; IL: interleukin; OCS: oral corticosteroid; TSLP: thymic stromal lymphopoietin. ^#In randomised control trials, there was a greater decrease in exacerbations in patients with blood eosinophil levels of ≥260 cells·μL⁻¹ (omalizumab versus placebo) [115, 127]. ^¶The higher the eosinophil level, the higher the expected impact. ^§Anti-TSLP not approved in patients with asthma at time of publication. Reproduced and modified from [77].